Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Enzymatica AB's
Operating Income
for the
three
months ended in Mar. 2026 was €-1.26 Mil. Enzymatica AB's Interest Expense for the
three
months ended in Mar. 2026 was €-0.01 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Enzymatica AB's Interest Coverage or its related term are showing as below:
STU:EN9's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.725 * Ranked among companies with meaningful Interest Coverage only.
Enzymatica AB (STU:EN9) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Enzymatica AB Interest Coverage Related Terms
Enzymatica AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:EN9 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Enzymatica AB did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Enzymatica AB (STU:EN9) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Enzymatica AB and its competitors. According to the industry distribution chart, Enzymatica AB ranks #999999 out of 686 companies in the Drug Manufacturers industry.
Is Enzymatica AB's Interest Coverage too high?
Enzymatica AB's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Enzymatica AB ranks #999999 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enzymatica AB has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #999999 out of 686 companies for Interest Coverage. This places Enzymatica AB in the lower half of its industry. The industry median Interest Coverage is 12.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Enzymatica AB (STU:EN9) has a current Interest Coverage of 0 (At Loss). The stock's GF Value™ is €0.16, compared to a current price of €0.19 — trading 16.9% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Enzymatica AB's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Enzymatica AB (STU:EN9), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (STU:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued.
The current stock price of €0.19 is trading 16.9% above its estimated GF Value™ of €0.16.
Key valuation signals for STU:EN9:
Interest Coverage: 0 (At Loss)
GF Value™: €0.16 vs. price of €0.19 (16.9% above fair value)
No single metric tells the full story. See the STU:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
57GF Score
Get the complete analysis for STU:EN9
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EN9 has been successfully added to your 
